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Background: Experimental data suggest that catecholamine hormones are involved in stimulating the
aggressiveness of ovarian cancer, but few population-based studies have examined this association. We therefore
conducted a population-based cohort study to examine whether ß-blockers affect mortality following ovarian
cancer diagnosis.
Methods: We used the Danish Cancer Registry to identify all patients diagnosed with ovarian cancer in northern
Denmark between 1999 and 2010 (n=6,626). Data on medication use, comorbidity, and survival were obtained from
medical databases. According to the last redeemed prescription before diagnosis, ß-blocker use was categorized as
current (within ≤90 days), previous (>90 days) or never. We used Cox proportional hazards regression to calculate
hazard ratios (HRs) for all-cause mortality with 95% confidence intervals (CIs) adjusting for confounding factors.
Results: Among the ovarian cancer patients, 373 (5.6%) were current, 87 (1.3%) previous, and 6,166 (93.1%) were
nonusers of ß-blockers. Median duration of use was 19.0 months among current users and 43.0 months among
previous users. Median follow-up was 2.55 years (IQR: 0.81-9.23). Nonusers and current users of ß-blockers had
similar comorbidity burden whereas previous users had moderate comorbidity more frequently. Compared with
nonusers, the adjusted HR was 1.17 (95% CI: 1.02–1.34) for current users and 1.18 (95% CI: 0.90–1.55) for previous
users. Secondary analyses stratifying by cancer stage and duration of ß-blocker use supported the overall results.
Conclusions: We found no evidence that ß-blocker use was associated with decreased mortality following ovarian
cancer diagnosis.Background
Inhibiting the sympathetic actions of catecholamine
hormones (i.e., epinephrine and norepinephrine), ß-blockers
are used for various indications, particularly cardiac
arrhythmias, cardioprotection after myocardial infarction,
hypertension, migraine, and tremor [1]. These diverse
indications reflect the abundance of ß-adrenoceptors in the
body. Experimental evidence shows that malignant cell lines
from, e.g., ovarian cancer and malignant melanoma also
express ß-adrenoceptors and that catecholamine stress* Correspondence: saj@dce.au.dk
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distribution, and reproduction in any mediumhormones may affect carcinogenesis through these re-
ceptors [2-8].
Previous research on the association between ß-blocker
use and mortality following malignant melanoma, have
shown consistent results between the protective effects
observed ex-vivo and in a population-based setting [7-9].
However, data on the effect of ß-blockers on mortality
following ovarian cancer in a population-based setting are
sparse [10]. We therefore conducted a population-based
cohort study to examine whether use of ß-blockers are
associated with mortality in patients with ovarian cancer.
Methods
Setting
The Danish National Health Service guarantees the entire
Danish population universal tax-supported health careCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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well as partial reimbursement of various drugs including
ß-blockers [11-13]. All individuals residing in Denmark at
any point in time since 1968 are assigned a unique central
personal registration (CPR) number, which is used to rec-
ord health-related services in various nationwide registries
and allows accurate and unambiguous individual-level
linkage of all registries [13].
We conducted this population-based cohort study in
northern Denmark (population 1.7 million, ≈30% of the
Danish population). This region encompasses the former
North Jutland County, Aarhus County, Viborg County
and Ringkøbing County for which complete computerized
prescription records are available through the Aarhus Uni-
versity Prescription Database since 1 January 1998 [12]. By
starting the study period on 1 January 1999, we ensured a
minimum of one year of prescription history for all
participants in the study.
Study cohort
The Danish Cancer Registry (DCR) has recorded infor-
mation on all incident malignant neoplasms in Denmark
since 1943 [14]. Tumors are classified according to the
7th revision of the International Classification of Diseases
(ICD-7) from 1943 through 2003 and according to the
10th revision thereafter [14].
We used the DCR to identify all women with a first-
time diagnosis of ovarian cancer from 1 January 1999 to
31 December 2010. We also included information on stage
at diagnosis according to the Summary Staging classifica-
tion with the TNM grouping translated as follows:
localized (TNM: T1–4, N0, M0), regional (TNM: Tx, N1–
3, M0), distant (TNM: Tx, N1–3, M1), or unknown/
missing. We included only women aged 20 years or more
at time of diagnosis.
ß-blocker use
Using the Aarhus University Prescription Database [12],
we identified all prescriptions for ß-blockers redeemed by
study subjects before their diagnosis date. For each pre-
scription dispensed, the patient’s CPR number, type and
amount of drug prescribed according to the Anatomical
Therapeutic Chemical (ATC) classification system, and
date of dispensation, are recorded in the electronic
accounting system at the pharmacy and subsequently
transferred to the database [12].
We defined three exposure categories: (1) current users
were those redeeming at least one prescription within 90
days of ovarian cancer diagnosis, (2) previous users were
those redeeming their last prescription in the interval 91
to 365 days prior to ovarian cancer diagnosis, and (3)
nonusers were those with no prescription records of ß-
blocker use within 365 days of ovarian cancer diagnosis.
We assessed exposure status prior to diagnosis to avoidintroducing immortal time bias, i.e., that users would ap-
pear to survive longer because a user by definition had to
survive to become a user [15]. We chose to assess expos-
ure prior to diagnosis to mimic an intention-to-treat
method [9] and because we hypothesized that ß-blockers
exert an inhibitory effect early in ovarian cancer progres-
sion. In Denmark, most prescriptions cover 30 to 90 days.
To assure that we captured most current users, we there-
fore chose 90 days as the exposure window.
Other patient characterstics
We used the Aarhus University Prescription Database to
obtain information on comedication use of the following
agents between establishment of computerized prescription
registries in each county and the date of ovarian cancer
diagnosis: angiotensin-converting enzyme (ACE) inhibitors,
calcium channel blockers, diuretics, statins, antidepressant
drugs, antipsychotics, anxiolytic drugs, and hormone re-
placement therapy. Over-the-counter use of aspirin and
low-dose ibuprofen is not recorded in the database [12].
However, regular users are typically registered in the pre-
scription database because the cost is automatically partly
refunded when a physician prescribes the drug [12].
The Danish National Registry of Patients (DNRP) has
recorded all inpatient admissions to non-psychiatric hos-
pitals since 1977, and all outpatient and emergency
admissions since 1995 [16]. Each record includes informa-
tion on dates of admission and discharge, diagnosis codes
and associated surgical procedures [16]. Diagnoses are clas-
sified according to ICD-8 through 1993 and the ICD-10 re-
vision thereafter [16]. Surgical procedures are recorded
using a Danish version of the Nordic Medico-Statistical
Committee (NOMESCO) Classification of Surgical Pro-
cedures [16]. We used the DNPR to retrieve information
on any diagnosis of obesity, atrial fibrillation/flutter, angina
pectoris, myocardial infarction, congestive heart failure,
esophageal varices, tremor, anxiety, thyrotoxicosis, chronic
obstructive pulmonary disease (COPD), migraines, stroke,
chronic kidney disease, or a history of hysterectomy or
tubal sterilization prior to ovarian cancer diagnosis. We also
measured the comorbidity burden using the Charlson
Comorbidity Index (CCI) categorized as low (score 0),
moderate (score 1–2), or high (score ≥3). The CCI is an ex-
tensively studied and validated instrument used to predict
the risk of death from comorbid diseases, by covering and
weighing 19 major chronic disease categories based on the
relative risk of dying [17-21].
All ICD and ATC codes used in the study are provided
in the Additional file 1: ATC and ICD codes.
Mortality
We started follow-up on the date of diagnosis and
continued until death, emigration, or end of follow-up
(31 December 2010) whichever came first. We identified
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System. The Danish Civil Registration System was estab-
lished on 1 April 1968 and includes daily updates on
changes in migration and vital status for the entire Danish
population [13].
Statistical analysis
Initially, we computed the frequency and proportion of
covariates, number of deaths, and amount of accu-
mulated person-time within categories of ß-blocker use.
Using time since diagnosis as the time scale, we then
used Cox proportional hazard regression to estimate
hazard ratios (HRs) with 95% confidence intervals (CIs)
associating ß-blocker use with mortality both overall and
according to stage at diagnosis. We used a risk-factor
modeling approach to fit a multivariable model. Age
group (20–40, 41–60, 61–80, and >80 years) and CCI
level were variables of interest a priori and therefore
included in the model from the start. Adding the
remaining variables to the model one at the time
resulted in a less than 10% change in the HR associated
with ß-blocker use. However, including prior use of
diuretics, aspirin, and statins, collectively in the model
demonstrated substantial confounding (>10%) and they
were therefore included in the model. We then tested
for statistically significant interactions between any of
the covariates and ß-blocker use. We assessed the as-
sumption of proportional hazards by graphical examin-
ation of log-log plots and found it not to be violated.
We performed two secondary analyses according to
duration of use (calculated as time between first and last
prescription plus 90 days). First, we made a restriction to
current users with at least one year of ß-blocker use and
compared them to non-users. Second, we examined the
association between ß-blockers and mortality following
ovarian cancer according to months of use among all user
groups. To ensure at least five years of prescription history
and thereby limit left censoring, this analysis was
restricted to women diagnosed in 2003–2010. The method
of fractional polynomials was used to confirm that months
of use, was linear in the log-hazard function.
We performed all analyses using STATAW software
(version 11.0, STATA, College Station, TX). The study was
approved by the Danish Data Surveillance Authority.Results
Patients characteristics
Table 1 presents the characteristics of the 6,626 ovarian
cancer patients included in the study. Median age at
diagnosis was overall 65 years (between 63–66 years
for all exposure groups). There were 6,166 (93.1%)
nonusers, 373 (5.6%) current users, and 87 (1.3%) previ-
ous users of ß-blockers in the cohort (Table 1). Themedian duration of use was 19.0 months among current
users and 43.0 months among previous users (Table 1).
Current and previous users of ß-blockers had more
frequently localized stage at the time of diagnosis than
nonusers. Stage was unknown/missing for 7.6% of
nonusers, 9.9% of current users, and 11.5% of previous
users. Nonusers and current users of ß-blockers had
similar comorbidity burden whereas previous users had
more frequently moderate comorbidity. Current and
previous users of ß-blockers more frequently used the
comedications identified.
Mortality
Overall the median follow-up time was 2.55 years (IQR:
0.81-9.23). Compared with nonusers, the adjusted HR
was 1.17 (95% CI: 1.02–1.34) for current users and 1.18
(95% CI: 0.90–1.55) for previous users (Table 2). When
examining the association according to stage at time of
diagnosis, we found similar results (Table 2).
There were no statistically significant interactions be-
tween any of the covariates and ß-blocker use, except
for age. To examine the clinical relevance, we therefore
stratified the results by age group. Although rather im-
precise, the estimates indicated a tendency towards
higher HRs in older age groups (Table 1 in Additional
file 2: Tables for secondary analyses and stratification by
age). The imprecise estimates for the age group below
40 years, made this strata inconclusive.
The secondary analysis showed that the results for
current users with ≥1 year duration of use were not sub-
stantially different from the results including all current
users (Table 2 in Additional file 2: Additional tables).
There was no association between months of use
entered as a linear variable and mortality following
ovarian cancer (HR 1.01; 95% CI: 1.00–1.01, Table 3 in
Additional file 2: Additional tables).
Discussion
In this population-based cohort study, we found no evi-
dence of an association between ß-blocker use and
decreased mortality following a diagnosis of ovarian
cancer.
Previous in vitro data on cancer cell lines suggest that
ß-blockers exert an antitumor effect via direct action on
ovarian cancer cells [2-4]. It has been shown that treat-
ment with adrenergic agonists could upregulate the pro-
duction of matrix metalloproteinase (MMP)-2, MMP-9,
and VEGF in ovarian cancer cell lines resulting in in-
creased invasive capability [2,4]. This effect was mediated
through ß-adrenoceptors and was blocked by treatment
with the ß-antagonist propranolol [2,4]. Similar results
have been found for other malignancies, e.g., malig-
nant melanoma, multiple myeloma, and nasopharyngeal
carcinoma [5-8,22-25]. Finally, it has been shown that
Table 1 Ovarian cancer patient demographics by ß-blocker use
Nonusers Current users Previous users
Number (%) 6,166 (93.06) 373 (5.63) 87 (1.31)
Age at diagnosis, years
Median age (IQR) 65 (56–75) 66 (56–74) 63 (55–73)
20-40 213 (3.45) 13 (3.49) 1 (1.15)
41-60 1,982 (32.14) 118 (31.64) 32 (36.78)
61-80 3,188 (51.70) 197 (52.82) 42 (48.28)
>80 783 (12.70) 45 (12.06) 12 (13.79)
Stageb
Localized 1,848 (29.97) 128 (34.32) 28 (32.18)
Regional 1,931 (31.32) 97 (26.01) 16 (18.39)
Distant 1,920 (31.14) 111 (29.76) 33 (37.93)
Unknown/missing 467 (7.57) 37 (9.92) 10 (11.49)
Comorbidity levelc
Low 4,127 (66.93) 251 (67.29) 58 (66.67)
Moderate 1,512 (24.52) 88 (23.59) 26 (29.89)
High 527 (8.55) 34 (9.12) 3 (3.45)
Comorbidities
Hypertension 681 (11.04) 45 (12.06) 12 (13.79)
Obesity 71 (1.15) 2 (0.54) 0 (0.00)
Atrial fibrillation/flutter 222 (3.60) 22 (5.90) 8 (9.20)
Angina pectoris 257 (4.17) 9 (2.41) 0 (0.00)
Myocardial infarction 160 (2.59) 10 (2.68) 2 (2.30)
Congestive heart failure 183 (2.97) 12 (3.22) 4 (4.60)
Esophageal varices 5 (0.08) 1 (0.27) 0 (0.00)
Tremor 4 (0.06) 0 (0.00) 0 (0.00)
Anxiety 41 (0.66) 1 (0.27) 1 (1.15)
Thyrotoxicosis 182 (2.95) 16 (4.29) 5 (5.75)
COPD 227 (3.68) 13 (3.49) 4 (4.60)
Migraines 78 (1.27) 3 (0.80) 2 (2.30)
Stroke 223 (3.62) 21 (5.63) 4 (4.60)
Chronic kidney disease 81 (1.31) 5 (1.34) 3 (3.45)
Hysterectomy 358 (5.81) 24 (6.43) 7 (8.05)
Tubal sterilization 204 (3.31) 11 (2.95) 3 (3.45)
Comedication use
ACE-inhibitors 351 (5.69) 104 (27.88) 30 (34.48)
ARBs 198 (3.21) 60 (16.09) 16 (18.39)
Calcium channel blockers 407 (6.60) 112 (30.03) 31 (35.63)
Diuretics 1,276 (20.69) 234 (62.73) 67 (77.01)
Non-aspirin NSAIDs 1,852 (30.04) 220 (58.98) 51 (58.62)
Aspirin 525 (8.51) 157 (42.09) 40 (45.98)
Statins 320 (5.19) 111 (29.76) 28 (32.18)
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Table 1 Ovarian cancer patient demographics by ß-blocker use (Continued)
HRT 1,165 (18.89) 126 (33.78) 33 (37.93)
Antipsychotics 336 (5.45) 41 (10.99) 8 (9.20)
Anxiolytics 285 (4.62) 22 (5.90) 7 (8.05)
Antidepressants 816 (13.23) 100 (26.81) 24 (27.59)
ACE: angiotensin-converting enzyme; ARBs: angiotensin receptor blockers; NSAIDs: nonsteroidal anti-inflammatory drugs.
a Defined as time between first and last prescription plus 90 days (assumed to be the average length of prescription).
b Classified according to Summary Staging classification with the TNM grouping translated as localized (TNM: T1–4, N0, M0), regional (TNM: T1–4, N1–3, M0),
distant (TNM: T1–4, N1–3, M1), or unknown/missing.
c Computed using the Charlson Comorbidity Index (CCI) score categorized into low (0), medium (1–2), or high (3+).
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have lower VEGF levels possibly linking stress, and hence
ß-adrenergic agents, to tumor angiogenesis [3].
In a recent meta-analysis, the association between ß-
blocker use and cancer-related mortality was examined
and no association was found (odds ratio=0.93; 95% CI:
0.80–1.08) [26]. However, this study examined only the
association for cancer-related mortality overall [26]. To
our knowledge, only one previous study has examined
this association for ovarian cancer specifically [10]. Diaz
et al. [10] examined the association between ß-blockers
and disease progression and survival among 248 patients
with stage III or IV epithelial ovarian or primary periton-
eal cancer who had undergone primary exploratory
laparotomy followed by at least 6 cycles of platinum-
and taxane-based chemotherapy. They found an medianTable 2 Mortality hazard ratioa following ovarian cancer diag
stage at diagnosisb
Number of deaths (%) Median years
Overall
Nonusers 4,106 (66.59) 2.5
Current users 245 (65.68) 2.6
Previous users 55 (63.22) 2.1
Localized cancer
Nonusers 722 (39.07) 10.5
Current users 46 (35.94) 7.8
Previous users 13 (46.43) 7.0
Regional metastasis
Nonusers 1,409 (72.97) 2.5
Current users 75 (77.32) 2.2
Previous users 10 (62.50) 1.4
Distant metastasis
Nonusers 1,602 (83.44) 1.2
Current users 96 (86.49) 1.1
Previous users 24 (72.73) 1.8
CI: Confidence interval.
a Obtained using Cox proportional hazards models.
b Classified according to Summary Staging classification with the TNM grouping tra
distant (TNM: T1–4, N1–3, M1), or unknown/missing.
c Adjusted for age (20–40, 41–60, 61–80, ≥80 years), comorbidity level, prior use of
Comorbidity was computed using the Charlson Comorbidity Index score categorizesurvival of 56 months for ß-blocker users compared with
48 months for non-users [10]. However, the interpretabilty
of the results is hampered for several reasons. First, the
study included a selected patient population, which limits
generalizability. Second, the improved survival seemed
confined to the later part of follow-up (more than 2–3
years), which is associated with statistical uncertainty be-
cause only few patients survived that long. Finally, and most
importantly, because authors’ decided that to be considered
as exposed a patient had to have used ß-blockers for at least
6 months, they also had to have survived at least 6 months,
and therefore immortal time bias may entirely explain the
increased survival among ß-blocker users [10,15]. By
assessing exposure prior to start of follow-up, we cir-
cumvented this problem in our study, which did not sup-
port any effect on the mortality rate after ovarian cancernosis associated with ß-blocker use, overall and by cancer
of follow-up Crude HR (95% CI) Adjusted HR (95% CI)c
6 1 (reference) 1 (reference)
5 1.04 (0.91–1.18) 1.17 (1.02–1.34)
4 1.03 (0.79–1.35) 1.18 (0.90–1.55)
8 1 (reference) 1 (reference)
7 0.97 (0.72–1.31) 1.01 (0.73–1.39)
7 1.44 (0.83–2.50) 1.57 (0.90–2.76)
4 1 (reference) 1 (reference)
1 1.21 (0.96–1.52) 1.52 (1.18–1.95)
2 0.95 (0.51–1.77) 0.89 (0.46–1.69)
5 1 (reference) 1 (reference)
0 1.09 (0.89–1.35) 1.18 (0.95–1.47)
6 0.70 (0.47–1.05) 0.91 (0.60–1.37)
nslated as localized (TNM: T1–4, N0, M0), regional (TNM: T1–4, N1–3, M0),
diuretics (yes/no), year of diagnosis, aspirin (yes/no), and statins (yes/no).
d into low (0), medium (1–2), or high (3+).
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cannot rule out an increased or decreased mortality for in-
dividual agents or certain histological types of ovarian can-
cer. Furthermore, given the wide confidence intervals and
the non-randomized design, we are unable to exclude a
small protective effect on mortality following ovarian can-
cer diagnosis.
Several issues should be considered when interpreting
our results. The study’s population-based design within the
setting of a tax supported universal healthcare system
reduces selection biases. Also, we were able to link
population-based registries with complete data on drug use,
cancer diagnosis, outpatient visits, and hospitalizations
[12,14,19,27,28]. For example, the positive predictive values
of diagnoses in the Danish National Registry of Patients
have previously been validated and found to exceed 98% for
Charlson comorbidities overall [19].
Data in the prescription database are virtually complete
[12]. Although we had to use prescription data as a proxy
for actual ß-blocker use, we did not base drug exposure
information on prescription filling, but on actual dispens-
ing at pharmacies [12]. Furthermore, we believe that
copayment requirements increased the likelihood of com-
pliance. However, any misclassification of drug exposure
would most likely have been nondifferential and thus
could, in part, explain the null result.
We were only able to consider all-cause mortality. We
did not have any biological explanation to support that
ß-blocker use would increase mortality rates following
ovarian cancer. Thus, multiple comparisons may explain
the slightly increased point estimates observed in some
exposure categories. These estimates may also have
resulted from uncontrolled confounding, as it is plaus-
ible that ß-blocker users on average are unhealthier than
nonusers. However, the universal provision of health
care considerably reduces the likelihood of substantial
confounding by social characteristics. Furthermore, we
did adjust partly for lifestyle factors by taking a history
of obesity, COPD and ischemic heart disease into ac-
count. Still, due to the nonrandomized design, we can-
not exclude uncontrolled confounding.
Conclusions
In conclusion, the present population-based cohort
study does not provide evidence of an association be-
tween ß-blocker use and decreased mortality following a
diagnosis of ovarian cancer.
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